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Summary
PRINCIPLES: Reimbursement for inpatient treatment in
Switzerland is in transition. While hospitals in some can-
tons already use Diagnosis Related Groups (DRG) based
systems for hospital financing, others use fee-for-service
(FFS) based systems, a situation that provides the oppor-
tunity to perform a head-to-head comparison between the
two reimbursement systems. The aim of this analysis was
to compare reimbursement systems with regard to length
of hospital stay (LOS) and patient outcomes in a cohort of
community-acquired pneumonia patients from a previous
prospective multicentre study in Switzerland.
METHODS: This is a post-hoc analysis of 925 patients
with community-acquired pneumonia from a previous
randomised-controlled trial. We calculated multivariate re-
gression models adjusted for age, gender, comorbidities
and severity of illness (using the Pneumonia Severity In-
dex) and accounting for clustering within hospitals to com-
pare LOS and outcomes between FFS (n = 4) or DRG hos-
pitals (n = 2).
RESULTS: LOS in DRG hospitals was significantly short-
er compared to FFS hospitals (8.4 vs 10.3 days, absolute
difference 1.9 days [95%CI 0.8–3.1]). This was confirmed
in multivariate adjusted Cox models (hazard ratio 1.2 [95%
1.1–1.3]). There were no differences in 30-day and
18-month mortality rates (adjusted odds ratio 1.7 [95%
0.9–3.2] and 1.3 [95% 0.9–1.9]) or recurrence rates within
30 days (adjusted odds ratio 0.8 [95% 0.4–1.7]). Also, no
differences were found in the rate of still ongoing clinical
symptoms at 30 days, satisfaction with the discharge pro-
cess and quality of life measures at 30 days of follow-up.
CONCLUSIONS: This study focusing on community-ac-
quired pneumonia patients with different severities found
a 20% shorter LOS in hospitals with DRG financing com-
pared to FFS hospitals without apparent harmful effects on
patient outcomes, satisfaction with care and different qual-
ity of life measures. Further studies are required to validate
these findings for other medical and surgical patient popu-
lations.
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Background
In Switzerland, the reimbursement system for inpatient
treatment is currently in transition. The Swiss Parliament
passed a law dictating that starting in 2012 a Diagnosis
Related Groups (DRG) hospital financing system based on
the German G-DRG system will replace the currently used
fee-for-service system (FFS) nationwide [1, 2]. Thus far,
DRG-based hospital reimbursement has not been simul-
taneously realised in all Swiss cantons: while hospitals in
some cantons currently already use DRG based systems
based on the 3M’s AP-DRG system for hospital financing
[3], others still use the traditional FFS based systems. This
situation provides the opportunity to perform a head-to-
head comparison between the two reimbursement systems.
While in FFS systems hospitals (and physicians in patients
with private insurance) receive reimbursement for each
health care service provided and for each additional day
of hospital stay, the DRG reimbursement system classifies
hospital cases into groups expected to have similar hospital
resource use as part of a prospective payment system. Thus,
while in the FFS system, hospitals and physicians have no
financial benefit when patients are discharged early, the op-
posite is true in DRG systems. Hence, the DRG system
is expected to create an incentive for hospitals and physi-
cians to reduce patient’s length of hospital stay (LOS) and
thereby curtail the increasing costs associated with in-hos-
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pital patient care [4–7]. Whether the quality of health care
within Switzerland will also be affected by this transition
is unclear and currently a matter of public debate and con-
cern [8, 9]. Most literature on this topic is based exclusively
on claims data and focuses on mortality and readmission
rates on a population level only, while patient-centred data
(such as individual satisfaction with care and quality of life
of patients) are scarce. Busato and von Below [2], for ex-
ample, used the complete dataset of all hospital discharges
in Switzerland (2003–2007) and corresponding claims data
to analyse differences of volume and major quality indic-
ators of care between areas with or without DRG-based
hospital reimbursement from a population based perspect-
ive. They found a (desired) shift to practice-based out-
patient care, but higher 90-day rehospitalisation rates of
almost 15% in areas with DRG reimbursement. Patient-
centred data were not available in this study and whether
DRG based systems negatively affected patients’ satisfac-
tion with care and quality of life remains unclear.
The aim of this analysis of community-acquired pneumo-
nia patients from a previous randomised-controlled mul-
ticentre trial [10, 11] was to compare LOS and patient
outcomes between hospitals with DRG systems and FFS
systems in Switzerland.
Methodology
Aims
The aim of this retrospective analysis was to investigate
differences in patient care and patient relevant outcomes in
FFS hospitals compared to hospitals that have already im-
plemented a SwissDRG reimbursement system in Switzer-
land.
Study design and setting
This is a post-hoc analysis including all 925 patients with a
definite diagnosis of community-acquired pneumonia from
a previous prospective randomised-controlled multicentre
trial [10]. A detailed study protocol has been published pre-
viously [11]. In brief, from October 2006 to March 2008,
from a total of 1825 potential patients, 1359 patients with
a presumptive diagnosis of a lower respiratory tract infec-
tion were consecutively enrolled in six different hospitals
located in the northern part of Switzerland. The aim of
the initial non-inferiority study was to compare length of
antibiotic therapy and outcomes in patients with respirat-
ory tract infections managed with a procalcitonin algorithm
compared to a control group. The main analysis was an
intention-to-treat analysis with imputation of the outcome
of one patient with missing follow-up information. Second-
ary aims were to investigate prognostic markers for blood
culture positivity and adverse outcomes [12–18] and pref-
erences of patients and physicians towards inhospital treat-
ment [19, 20]. Baseline characteristics of the six participat-
ing hospitals have previously been reported [11, 21]. Two
of these hospitals had, due to regulations in the respective
canton where they are located, an AP-DRG reimbursement
system based on the German G-DRG system [1, 2] in place
starting about 5 years before the study period, while the re-
maining four hospitals received reimbursement on a FFS
basis. This AP-DRG system is similar to systems used in
other countries, but in this transition period, these hospitals
were still protected from financial losses by the cantons.
The study protocol was approved by all of the local ethical
committees, and written informed consent was obtained
from all participants.
Selection of participants
Inclusion criteria were age >18 years and suspected lower
respiratory tract infection as principal diagnosis on admis-
sion. In accordance with guidelines, lower respiratory tract
infection was defined by the presence of at least one res-
piratory symptom plus at least one finding during ausculta-
tion, or one sign of infection [22, 23]. Community-acquired
pneumonia was defined as a new infiltrate on chest X-
ray [22, 23]. Patients were examined on admission to the
emergency department by a resident supervised by a board-
certified specialist in internal medicine. The standardised
baseline assessment included medical history, clinical ex-
amination, lab tests and chest X-ray. For all patients with
community-acquired pneumonia, the Pneumonia Severity
Index (PSI) was calculated to assess disease severity [24].
The PSI categorises patients into 5 risk classes: those in
classes I–III (PSI ≤90 points) designate lower risk patients
with an estimated mortality of about 0.3%, 0.6% and 0.9%
and those in classes IV–V (PSI >90 points) represent high
risk individuals with an estimated mortality of around 10%
and 30%, respectively. Within the study, the decision to
discharge patients was left to the discretion of the treating
physicians without interference of the study team.
Patient outcomes
Patients were monitored by the study team during their hos-
pital stay and blinded medical students performed struc-
tured phone interviews at 30, 180 days and at 18 months
after enrolment to assess outcomes [29]. LOS was defined
as the time from admission to hospital until discharge or
death. To measure changes in mortality we used all-cause
mortality within 30 days and 18 months; recurrent infection
was defined as radiologically, microbiologically or clin-
ically confirmed recurrence of infection requiring antibi-
otics as judged by the treating physician (primary care
physicians or hospital physician). These outcomes were
monitored by an independent Data Safety and Monitoring
Board. In case a patient could not be reached, we contacted
the patient’s family or the primary care physicians to verify
the survival status.
Patients were also asked during the interview on day 30
about on-going discomfort related to the initial infection
and about satisfaction with the discharge process including
whether timing of discharge was appropriate as part of a
secondary study aim [19, 20]. We further assessed quality
of life as measured with the EQ-5D instrument [25]. The
EQ-5D includes the 15-item tool EQ-5Dself-classifier which
assesses the health related quality of life along five dimen-
sions (mobility, self-care, usual activities, pain/discomfort
and anxiety/depression) and also allows calculation of a
weighted Quality of life index [26]. During the 30 days fol-
low up, 1 patient was lost to follow up. Between 5–10% of
patients did prefer not to respond to at least one question
about quality of life or satisfaction with care; these patients
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were excluded from the respective analysis (complete case
analysis).
Statistics
We used descriptive statistics including mean with standard
deviation and frequencies to describe the populations, as
appropriate. We compared LOS in FFS and DRG hospitals
stratified by disease severity using the PSI [24]. We calcu-
lated Cox proportional hazard models to assess the asso-
ciation of reimbursement system and time to hospital dis-
charge adjusted for disease severity (PSI), age, gender and
important comorbidities (congestive heart failure, chronic
renal failure, chronic obstructive pulmonary disease) and
also adjusting for clustering of patients within hospitals.
We also investigated whether patients’ types of medical in-
surance (basic or private) have an influence on LOS by
inclusion of an interaction term between insurance type
and hospital financing system to exclude effect modifica-
tion. Generalised estimating equation (GEE) method was
applied for outcome evaluation between the two reimburse-
ment systems accounting for clustering within hospitals.
All models were adjusted for disease severity (PSI), age,
gender and comorbidities.
Results
Figure 1
Length of Hospital stay according to severity of pneumonia in
hospitals with a FFS system (light gray) or a DRG system (dark
gray); asterisk refers to significant difference of FFE compared to
DRG hospital.
Figure 2
Forest plot showing individual outcomes (separately analysed)
according to hospital reimbursement; of note, odds ratios = 0
indicate no effect, while odds ratios >1 indicate a positive
association between the exposure variable and hospitals with DRG
financing systems; models are adjusted for age, gender, severity
(PSI) and comorbidities (congestive heart failure, COPD, chronic
renal failure) and account for clustering of patients within hospitals.
Baseline characteristics
This study included 925 patients with a definite diagnosis
of community-acquired pneumonia enrolled in either one
of four FFS hospitals (n = 666) or one of two DRG based
hospital (n = 259). There was no difference in terms of pa-
tient age and gender or previous health history. The patient
population in DRG hospitals had higher rates of chronic
renal failure (27% vs 20%) and lower rates of congestive
heart failure (11% vs 19%) as compared to FFS hospitals.
There was no difference in the distribution of severity of
disease as assessed with the PSI. Baseline characteristics of
the population overall and stratified by hospital financing
type are displayed in table 1.
Differences in length of hospital stay
Overall, LOS in DRG hospitals was about 20% shorter
compared to FFS hospitals (8.4 vs 10.3 days, absolute dif-
ference 1.9 days [95%CI 0.8–3.1], p <0.001). As shown in
figure 1, this difference was most pronounced in the sub-
group of patients with PSI classes III and IV. A signific-
antly shorter LOS in DRG hospitals was also confirmed
in multivariate Cox models for time to discharge of pa-
tients (hazard ratio 1.20 [95% 1.11–1.32]) adjusted for age,
gender, severity (PSI) and comorbidities. Note, hazard ra-
tios higher than 1 indicate an association of the factor with
shorter LOS. This result remained robust when restricting
to hospital survivors only (data not shown).
We also investigated whether the 19% of patients (n = 174)
with private medical insurance had a different LOS than
patients with only basic insurance and whether this associ-
ation was different in FFS and DRG hospitals. We found no
association between insurance type and LOS (hazard ratio
of private insurance 1.1 (95%CI 0.9–1.2) and no evidence
for effect modification by type of hospital financing system
(p of the interaction term = 0.27).
Patient outcomes
Table 2 shows outcomes of patients being treated in FFS
hospitals and DRG hospitals. There was no significant dif-
ference in 30 days and 18 month mortality rates (adjusted
odds ratio 1.7 (95%CI 0.9–3.2) and 1.3 (95%CI 0.9–1.9)
and both groups had similar recurrence rates (adjusted odds
ratio 0.8 [95% 0.4–1.7]) (fig. 2). Also, a similar proportion
of patients in both groups still experienced discomfort re-
lated to the initial infection, namely respiratory symptoms,
dyspnoea or were generally not feeling well. The majority
of patients in both groups were satisfied with the discharge
process with no differences between hospitals: 14% and
10% of patients in FFS and DRG hospitals indicated that
discharge was too early (adjusted odds ratio 1.4, 95%CI
0.9–2.3). Finally we also compared quality of life after
30 days in both groups using the EQ-5D questionnaire.
There was no difference in the weighted quality-of-life in-
dex [26] between FFS and DRG hospitals (0.82 vs 0.83,
absolute difference –0.007 [95%CI –0.04–0.02], p = 0.64).
Also, there was no significant difference in any of the
5 documented quality-of-life domains (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
(see fig. 3).
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Discussion
Within this study focusing on community-acquired pneu-
monia patients from a previous multicentre trial, we in-
vestigated differences in LOS and patient relevant outcome
between FFS hospitals and DRG hospitals. We found sig-
nificant shorter LOS of about 20% in hospitals that used
DRG reimbursement system. In the Swiss health care sys-
tem, one in-hospital day costs roughly 1000–1200 USD;
thus the observed reduction in LOS amounts to about
2000 USD per patient from a total patient cost of around
10’000 USD. Although our study was not powered to de-
tect small differences in rare outcomes such as mortality,
we found no apparent harm associated with hospitals using
DRGs in regard to short and long term mortality, recur-
rence rate, patient satisfaction with the discharge process
and different quality of life measures.
The DRG system was developed at Yale University to
provide hospitals with incentives to focus more on costs [4,
5]. Hospital Medicare inpatients are classified into groups
Table 1: Baseline characteristics of patients with community-acquired pneumonia according to hospital reimbursement system.
All patients
(n = 925)
FFS hospitals
(n = 666)
DRG hospitals
(n = 259)
P
Demographics
– Age (years)*
– Sex (male) – no. (%)
68 (±17.8)
544 (59%)
68 (±17.8)
390 (58%)
66 (±18.2)
154 (59%)
0.06
0.80
Co-existing illnesses – no. (%)
– Congestive heart failure
– Renal failure
– COPD
– Diabetes
159 (17%)
206 (22%)
282 (30%)
162 (18%)
130 (19%)
135 (20%)
211 (32%)
110 (17%)
29 (11%)
71 (27%)
71 (27%)
52 (20%)
<0.01
0.02
0.21
0.20
Previous history – no. (%)
– Former or current smoker
– Previous Treatment with AB
– History of fever
– History of chills
233 (26%)
236 (26%)
618 (67%)
301 (37%
164 (25%)
172 (26%)
456 (69%)
214 (37%)
69 (27%)
64 (25%)
162 (63%)
87 (37%)
0.63
0.18
0.06
0.96
Clinical findings
– Confusion – no. (%)
– Respiratory rate (b/min)*
– Systolic BP (mm Hg)*
– Heart rate (beats/minute)*
– Body temperature (C°)*
74 (9%)
22 (±9)
133 (±19)
96 (±18)
38.1 (±1,1)
57 (9%)
23 (±9)
134 (±22)
96 (±21)
38.1 (±1,1)
17 (7%)
21 (±8)
129 (±21)
95 (±20)
37.8 (±1.1)
0.33
0.06
<0.01
0.38
<0.01
Severity of disease
PSI points*
PSI class – no. (%)
– I, II, III
– IV
– V
92 (±36)
452 (49%)
349 (38%)
124 (13%)
93 (±36)
314 (47%)
126 (39%)
92 (14%)
90 (±37)
138 (53%)
89 (34%)
32 (12%)
0.25
0.38
COPD, chronic obstructive pulmonary disease; BP, blood pressure; PSI Pneumonia Severity Index; *expressed as mean (± standard deviation); AB, antibiotics
P values refer to t-tests and chi-square tests
Table 2: Patient outcomes with regard to hospital type.
Outcome FFS hospital patients DRG hospital patients Adjusted* odds ratio
(95%CI)
p value
All-cause mortality, % (n)
30–day mortality 4.8% (32/666) 6.9% (18/259) 1.7 (0.9, 3.2) 0.127
18–month mortality 21.0% (140/666) 23.2% (60/259) 1.3 (0.9, 1.9) 0.16
Recurrent respiratory infection within 30 days, % (n)
Primary care physician visit for suspected recurrent infection 9% (60/605) 9% (22/234) 0.9 (0.5, 1.6) 0.734
Confirmed recurrent infection in need of antibiotics 5% (30/666) 4% (9/259) 0.8 (0.4, 1.7) 0.499
Ongoing discomfort at 30 days, % (n)
Still experiencing any respiratory symptoms 40% (248/626) 39% (92/238) 0.9 (0.6, 1.3) 0.634
Dyspnoea not improved 23% (138/612) 22% (52/232) 1.0 (0.7, 1.4) 0.879
General well-being not improved 8% (55/614) 6% (15/233) 0.7 (0.4, 1.3) 0.247
Satisfaction with discharge process, % (n) 0.08
Satisfied with discharge process 83% (483/585) 83% (184/223)
Discharge was too late 7% (42/585) 4% (8/223) 0.5 (0.2, 1.1) 0.096
Discharge was too early 10% (60/585) 14% (31/223) 1.4 (0.9, 2.3) 0.147
Quality of life (EQ-5D), % (n)
Any problems with mobility 33% (200/613) 31% (73/235) 1.0 (0.7, 1.4) 0.943
Any problems with self care 20% (124/618) 16% (38/237) 0.8 (0.6, 1.3) 0.439
Any problems with usual activities 34% (208/617) 37% (88/237) 1.4 (1.0, 1.9) 0.074
Any problems with pain/discomfort 31% (193/619) 35% (82/234) 1.2 (0.8, 1.9) 0.428
Any problems with anxiety/depression 16% (96/605) 19% (44/236) 1.3 (0.8, 1.9) 0.29
*models are adjusted for age, gender, severity (PSI) and comorbidities (congestive heart failure, COPD, chronic renal failure) and account for clustering of patients within
hospitals
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that are allegedly clinically coherent and homogenous with
respect to resource use. The classification is dependent on
principal and secondary diagnoses and procedures, age,
gender, and discharge status of the patient. Reimbursement
is flat-rate and determined by the way patients are classi-
fied. Hospitals can create excess revenues by treating the
patient more efficiently and economically, or conversely
absorb monetary losses. It is argued that hospitals will
become more frugal and that physicians will adjust their
methods of practice as well.
As a positive example, a Japanese study found that after
introduction of DRGs in 2003, women with breast cancer
were treated with shorter LOS for surgical therapy and
chemotherapy while maintaining the quality of care [27].
Still, whether DRG effectively reduces LOS in the general
population without negatively affecting patient outcomes is
a matter of controversy [28]. In addition, the influence of
DRGs on the quality of care and patient safety is a major
public concern. To ultimately answer this question, large
randomised-controlled trials allocating hospitals to either
reimbursement systems would be desirable, but are hardly
feasible. For these reasons, it is important that studies use
other trial designs, such as before-after designs, time-series
or quasi-experiments, to investigate the effects of DRGs on
patient outcomes. Also, qualitative studies grasping views
and perceptions on the influence of DRGs on the quality
of care are paramount. Large epidemiological studies have
used claims data to compare readmission and mortality
rates [2]. The strength of these analyses is the large sample
size with high statistical power, which allows detection of
even small differences in outcomes. Yet, these studies are
often hampered by lack of socio-demographic data and dis-
ease severity, which is necessary to adjust for confound-
ing. In addition, these studies often do not report patient-
specific outcomes, such as quality of life and satisfaction
with care. Our analysis of a large scale, well-defined and
characterised cohort of patients provides novel insights and
is thus noteworthy. Importantly, within our analysis we fo-
cused only on patients with community-acquired pneumo-
nia of different severities; further studies are required to
validate these findings for other medical and surgical pa-
tient populations.
Our data are especially worthy of attention, as they con-
stitute a timely baseline before the nationwide implement-
ation of DRGs. Switzerland is currently in a transition of
payment systems from mainly FFS hospitals to a DRG sys-
Figure 3
Quality of life according to reimbursement status; for all
comparisons there was no statistical significant difference (p <0.05
for all chi-square tests).
tem which will take place in 2012. Importantly, hospitals
that are currently using DRGs in Switzerland are still pro-
tected from financial losses by the cantons. Therefore, the
pressure to optimise patient care in general, and LOS in
particular, differs from what is expected to be implemented
as of 2012. Hence, the introduction of the SwissDRG may
still lead to other consequences based on the issue of ration-
ing at the bedside. It will be important to closely monitor
the quality of health care during this transition to prevent
negative effects on patients.
This study has some limitations. First, compared to large
population based studies, our cohort lacks the statistical
power to detect smaller differences in mortality and other
infrequent outcomes. This is of particular importance with
regard to type II errors (false negative results). Second, the
6 participating hospitals were all relatively large in size and
we do not know if our findings unconditionally apply to
smaller community hospitals. Also, this study is embedded
in the Swiss health care system and may not be valid for
other countries/health care systems. Third, although current
DRGs use varies regionally within Switzerland (in certain
cantons) as opposed to from hospital to hospital, differen-
ces in patients’ baseline characteristics may confound our
analysis. For this reason, we adjusted the analysis for dis-
ease severity using the validated PSI, socio-demographic
data and comorbidities. Still, we cannot exclude residual
confounding related to baseline differences of patients liv-
ing in cantons where DRG have been implemented. Fourth,
as a secondary analysis of a previous randomised study, se-
lection bias is an issue and specific patient populations (i.e.
immune-suppression, patients with dementia) were not in-
cluded in this study, which may limit the “generalizability"
of our results. Thus further research is needed to confirm
our findings.
In conclusion, this study focusing on community-acquired
pneumonia patients with different severities found a 20%
shorter LOS in hospitals with DRG financing compared to
FFS hospitals without apparent harmful effects on patient
outcomes and quality of life measures. Further studies are
required to validate these findings for other medical and
surgical patient populations.
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